Abstract
Aim
To compare the efficacy of pars plana vitrectomy (ppV) with intravitreal injection of recombinant tissue plasminogen activator (rtPA) and gas versus ppV with subretinal injection of rtPA and intravitreal injection of gas.
Methods
Nonrandomized, retrospective, interventional, comparative consecutive series including 47 patients with submacular hemorrhage. Eighteen patients were treated with ppV, intravitreal injection of rtPA and 20% SF6 gas [group A: mean age 78 years, mean duration of symptoms 6.6 days, 15 age-related macular degeneration (AMD), three retinal arterial macroaneurysm (RAMA)]. Twenty-nine patients were treated with ppV, subretinal injection of rtPA and intravitreal injection of SF6 gas (group B: mean age 75 years, mean duration of symptoms 5.9 days, 26 AMD, two RAMA, one blunt ocular trauma). The main outcome measure was complete displacement of submacular hemorrhage from the fovea.
Results
Complete displacement of submacular hemorrhage was achieved in less patients in group A (22%) than in group B (55%) (p = 0.025). In group A, mean best-corrected visual acuity (BCVA) change was logMAR -0.14, standard deviation (SD) = 0.64, and in group B logMAR -0.32, SD = 0.68 without statistically significant difference between the two groups (p = 0.2, Mann–Whitney test). Complications (retinal detachment, vitreous hemorrhage, and recurrence of submacular hemorrhage) were more frequent in group B than in group A.
Conclusion
ppV with subretinal injection of rtPA and intravitreal injection of gas was more effective than ppV with intravitreal injection of rtPA and gas in terms of complete displacement of submacular hemorrhage; however, it may be associated with a higher rate of postoperative complications. Functional improvement in the majority of patients suggests the absence of direct retinal toxicity of subretinally applied rtPA.


Similar content being viewed by others
References
Avery RL, Fekrat S, Hawkins BS et al (1996) Natural history of subfoveal hemorrhage in age-related macular degeneration. Retina 16:183–189
Scupola A, Coscas G, Soubrane G et al (1999) Natural history of macular subretinal hemorrahge in age-related macular degeneration. Ophthalmologica 213:97–102
Glatt H, Machemer R (1982) Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 94:762–773
Toth CA, Mourse LS, Hjemeland LM, Landers MB III (1991) Fibrin early retinal damage after experimental subretinal hemorrahge. Arch Ophthalmol 109:723–729
Gillies A, Lahav M (1983) Absorption of retinal and subretinal hemorrhages. Ann Ophthalmol 15:1068–1074
Bhisitkul RB, Winn BJ, Lee OT et al (2008) Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci 49:4071–4077
El Baba F, Jarrett WH (1986) Massive hemorrhage complicating age-related macular degeneration: Clinicopathologic correlation and role of anticoaggulants. Ophthalmology 93:1581–1592
Gabel VP (1991) Subretinal lavage in fresh hemorrhage in macular degeneration. Fortschr Ophthalmol 88:135–137 [German]
Vander JF, Federman JL, Greven C, Slusher MM, Gabel VP (1991) Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration. Ophthalmology 98:23–27
De Juan E Jr, Machemer R (1988) Vitreous surgery for hemorrhagic and fibrous complication of age-related macular degeneration. Am J Ophthalmol 105:25–29
Lewis H (1994) Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 118:559–568
Peyman GA, Nelson NC Jr, Alturki W et al (1991) Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg 22:575–582
Bressler NM, Bressler SB, Childs AL, Submacular Surgery Trials (SST) Research Group et al (2004) Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report No. 13. Ophthalmology 111:1993–2006
Chen CY, Hooper C, Chiu D, Chamberlain M, Karia N, Heriot WJ (2007) Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina 27:321–328
Hesse L, Schmidt J, Kroll P (1999) Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 237:273–277
Hassan AS, Johnson MW, Schneiderman TE et al (1999) Management of submacular hemorrhage with intravitreous tPA injection and pneumatic displacement. Ophthalmology 106:1900–1907
Handwerger BA, Blodi BA, Chandra SR, Olsen TW, Stevens TS (2001) Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement Arch Ophthalmol 119:28–32
Meyer CH, Scholl HP, Eter N et al (2008) Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 86:490–494
Kamei M, Misono K, Lewis H (1999) A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 128:739–746
Takeuchi A, Kricorian G, Yao XY et al (1994) The rate and source of albumin entry into saline-filled experimental retinal detachments. Invest Ophthalmol Vis Sci 35:3792–3598
Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J (2003) Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 44:2141–2146
Heiduschka P, Fietz H, Hofmeister S et al (2007) Penetration of Bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48:2814–2823
Haupert CL, McCuen BW 2nd, Jaffe GJ (2001) Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 131:208–215
Olivier S, Chow DR, Packo KH (2004) Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration. Ophthalmology 111:1201–1208
Hattenbach LO, Klais C, Koch FHJ, Gümbel HOC (2001) Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology 108:1485–1492
Schulze SD, Hesse L (2002) Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome. Graefes Arch Clin Exp Ophthalmol 240:717–720
Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y (1998) Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 116:1326–1332
Lincoff H, Kreissig I, Stopa M et al (2008) A 40 degrees gaze down position for pneumatic displacement of submacular hemorrhage: clinical application and results. Retina 28:56–59
Johnson MW, Olsen KR, Hernandez E (1991) Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Retina 11:250–258
Acknowledgments
We thank Dipl.-Math. Elfriede Fritzer, Institute for Medical Statistics and Informatics, University of Kiel for expert statistical advice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hillenkamp, J., Surguch, V., Framme, C. et al. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 248, 5–11 (2010). https://doi.org/10.1007/s00417-009-1158-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-009-1158-7